Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection

The article presents the contemporary views of the role of aldosterone in the progression of cardiovascular and renal diseases. It addresses matters related to the efficacy and safety of mineralocorticoid receptor antagonists in patients with chronic heart failure, chronic kidney disease at various...

Full description

Bibliographic Details
Main Authors:	A. M. Esayan, A. N. Nimgirova
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2018-04-01
Series:	Медицинский совет
Subjects:	aldosterone mineralocorticoid receptor antagonists heart failure chronic kidney disease dialysis kidney transplantation
Online Access:	https://www.med-sovet.pro/jour/article/view/2357

Similar Items

Heart failure: the role for mineralocorticoid receptor antagonists
by: Bertram Pitt
Published: (2014-05-01)

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015
by: Yu F Osmolovskaya, et al.
Published: (2015-09-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Daiji Kawanami, et al.
Published: (2021-10-01)

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
by: S N Tereshchenko, et al.
Published: (2013-12-01)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
by: Monarch Shah, et al.
Published: (2023-09-01)

Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
by: Greg H. Tesch, et al.
Published: (2017-05-01)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
by: Yuta Tezuka, et al.
Published: (2021-03-01)

Spontaneous Remission of Primary Aldosteronism with Mineralocorticoid Receptor Antagonist Therapy: A Review
by: Xurong Mai, et al.
Published: (2022-11-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021-06-01)

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
by: Josefin Henrysson, et al.
Published: (2023-02-01)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
by: Memory MUKANGWA, et al.
Published: (2019-12-01)

Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
by: Asadur Rahman, et al.
Published: (2023-01-01)

Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients
by: Pascal R. D. Clephas, et al.
Published: (2023-04-01)

Potential of Modulating Aldosterone Signaling and Mineralocorticoid Receptor with microRNAs to Attenuate Diabetic Kidney Disease
by: Shinji Hagiwara, et al.
Published: (2024-01-01)

Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients
by: Takuro Abe, et al.
Published: (2020-10-01)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
by: Stephen eOrena, et al.
Published: (2013-10-01)

Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review
by: Natalia V. Safronova, et al.
Published: (2022-01-01)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
by: Wiktoria Baran, et al.
Published: (2021-09-01)

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
by: Ixchel Lima-Posada, et al.
Published: (2023-01-01)

Clinical application of mineralocorticoid receptor antagonists in chronic heart failure
by: MG Bubnova
Published: (2014-12-01)

Mineralocorticoid Receptor-Dependent Impairment of Baroreflex Contributes to Hypertension in a Mouse Model of Primary Aldosteronism
by: Luo Shi, et al.
Published: (2019-11-01)

Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis
by: Jean Kim, et al.
Published: (2022-03-01)

Mineralocorticoid Receptor Antagonism Attenuates Multiple Organ Failure after Renal Ischemia and Reperfusion in Mice
by: Eun Jung Park, et al.
Published: (2023-02-01)

Assessment of renal and cardiovascular risks in patients with type 2 diabetes when using non-steroidal mineralocorticoid receptor antagonists
by: V.М. Yerokhovych, et al.
Published: (2023-12-01)

The new Era of non-Steroidal Mineralocorticoid Antagonists in Treating Heart Failure in Diabetic Kidney Disease Patients.
by: Eqerem Hasani, et al.
Published: (2022-01-01)

Thiazides and mineralocorticoid receptor antagonists in chronic kidney disease
by: Andrei Niculae, et al.
Published: (2022-03-01)

Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure
by: Ida Löfman, et al.
Published: (2018-07-01)

Cardiac Mineralocorticoid Receptor and the Na+/H+ Exchanger: Spilling the Beans
by: Irene Lucía Ennis, et al.
Published: (2021-01-01)

Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
by: Sho Suzuki, et al.
Published: (2020-10-01)

Importance of Micromilieu for Pathophysiologic Mineralocorticoid Receptor Activity—When the Mineralocorticoid Receptor Resides in the Wrong Neighborhood
by: Bruno Griesler, et al.
Published: (2022-10-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

Aldosterone nongenomically induces angiotensin II receptor dimerization in rat kidney: role of mineralocorticoid receptor and NADPH oxidase
by: Kittisak Sinphitukkul, et al.
Published: (2019-08-01)

Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
by: Yichuan Wu, et al.
Published: (2022-09-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01)

MINERALOCORTICOID RECEPTOR ANTAGONISTS THERAPY IN RESISTANT HYPERTENSION: TIME TO IMPLEMENT NEW GUIDELINES?
by: Giuseppe eMaiolino, et al.
Published: (2015-02-01)

Mineralocorticoid Receptor Activation in Vascular Insulin Resistance and Dysfunction
by: Aderonke E. Igbekele, et al.
Published: (2022-08-01)

Mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy
by: Ana Sanhueza, et al.
Published: (2020-09-01)

Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses
by: Camila Q. Felipe, et al.
Published: (2022-06-01)

First Evidence of Mineralocorticoid Receptor Gene and Protein Expression in Rat and Human Thyroid Tissues and Cell Cultures
by: Jacopo Manso, et al.
Published: (2024-01-01)

FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes
by: M. S. Shamkhalova, et al.
Published: (2023-12-01)